Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies

On September 15, 2022 Integral Molecular, the industry leader in discovering antibodies against complex membrane protein targets, reported that it has licensed a panel of monoclonal antibodies (MAbs) to CARTEXELL, enabling CARTEXELL to develop CAR-T cell therapies using Integral Molecular’s Claudin 18.2 (CLDN18.2) MAbs (Press release, Integral Molecular, SEP 15, 2022, View Source [SID1234623334]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Integral Molecular will provide an exclusive worldwide license to CARTEXELL to use the panel of high-affinity, high-specificity, and fully humanized CLND18.2 MAbs for the development of CAR-T cell therapies against solid tumors including gastric, lung, pancreatic and esophageal cancers. CARTEXELL will be solely responsible for all research, development, and commercial activities.

The CLND18.2 MAbs were isolated using Integral Molecular’s MPS Antibody Discovery platform which is uniquely tailored to deliver high-specificity, high-affinity antibodies against the most structurally challenging membrane protein targets including GPCRs, ion channels, transporters, and tight junction proteins.

"Claudin 18.2 is an exciting target for oncology therapeutics since it’s highly expressed in cancers such as gastric and esophageal cancers that are difficult to treat", said Joseph Rucker, PhD, Vice President of R&D at Integral Molecular. "We look forward to the synergy of our high-specificity MAbs with CARTEXELL’s CAR-T cell therapy technology to bring new therapies to patients."

"CAR-T cell therapy has revolutionized treatment options for blood cancers, but has been ineffective for solid tumors", said Jehee Suh, CEO of CARTEXELL. "We are excited by the promise of these Claudin 18.2 antibodies for targeting our CAR-T 2.0 technology which uses engineered cells and vectors to overcome the tumor microenvironment and provide more effective therapies."